Both the Shanghai CMEF 2017 and Sao Paulo Hospitalar 2017 came to an end recently. As a global leading pharmaceutical and medical device B2B online platform, Ddu attended the two fairs, showcasing products of high priority users.
In which industry is the next unicorn company most likely to be born into? With the arrival of an aging society, medical trade is regarded as the industry with the most potential to produce a unicorn company.
Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
Drugdu Technology Co., Ltd., a developer of the leading global pharmaceutical and medical device B2B platform Drugdu.com (Ddu), today announced that it will attend Hospitalar 2017 from May 16 to 19 in Sao Paulo, Brazil. Drugdu.com will showcase products of premium members and deliver innovative solutions, which are attractive not only for its users, but for the whole healthcare industry.
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
WHO is improving transparency and accountability with the launch of a redesigned Programme Budget Web Portal that makes budget and spending information easier to access, use and understand.
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.